Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Peptide-based diagnostic and therapeutic agents: Where we are and where we are heading?
Date
2022-11-01
Author
PARLAK KHALİLY, MELEK
Soydan, Medine
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
142
views
0
downloads
Cite This
Peptides are increasingly present in all branches of medicine as innovative drugs, imaging agents, theragnostic, and constituent moieties of other sophisticated drugs such as peptide-drug conjugates. Due to new developments in chemical synthesis strategies, computational biology, recombinant technology, and chemical biology, peptide drug development has made a great progress in the last decade. Numerous natural peptides and peptide mimics have been obtained and studied, covering multiple therapeutic areas. Even though peptides have been investigated across the wide therapeutic spectrum, oncology, metabolism, and endocrinology are the most frequent medical indications of them. This review summarizes the current use of and the emerging new opportunities of peptides for diagnosis and treatment of various diseases.
Subject Keywords
peptide probes
,
peptide therapeutics
,
radiolabeled peptides
,
targeting
,
POSITRON-EMISSION-TOMOGRAPHY
,
IRON-OXIDE NANOPARTICLES
,
IN-VIVO EVALUATION
,
INTEGRIN ALPHA(V)BETA(3) EXPRESSION
,
STIMULATING HORMONE ANALOG
,
CELL-PENETRATING PEPTIDES
,
RADIOLABELED RGD PEPTIDES
,
CONJUGATED QUANTUM DOTS
,
PROSTATE-CANCER
,
IMAGING PROBES
URI
https://hdl.handle.net/11511/101491
Journal
CHEMICAL BIOLOGY & DRUG DESIGN
DOI
https://doi.org/10.1111/cbdd.14180
Collections
Department of Chemistry, Article
Suggestions
OpenMETU
Core
Bioactive agents carrying quantum dot labeled liposomes
Büyüksungur, Arda; Hasırcı, Vasıf Nejat; Padeste, Celestino; Department of Biotechnology (2013)
Among the many possible applications of nanotechnology in medicine, the use of various nanomaterials as delivery systems for pharmacologically active agents, drugs and nucleic acids (DNA, siRNA), and imaging agents is gaining increased attention. Liposomes are particularly important for these drug delivery systems because of their advantages such as their ability to carry hydrophilic and hydrophobic drugs, their being of biological origin and short life spans. Quantum Dots (QDs) are nano-scale, semiconducti...
Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
Sinaci, A. Anil; Laleci Erturkmen, Gokce B.; Gonul, Suat; Yuksel, Mustafa; Invernizzi, Paolo; Thakrar, Bharat; Pacaci, Anil; Cinar, H. Alper; Çiçekli, Fehime Nihan (Hindawi Limited, 2015)
Postmarketing drug surveillance is a crucial aspect of the clinical research activities in pharmacovigilance and pharmacoepidemiology. Successful utilization of available Electronic Health Record (EHR) data can complement and strengthen postmarketing safety studies. In terms of the secondary use of EHRs, access and analysis of patient data across different domains are a critical factor; we address this data interoperability problem between EHR systems and clinical research systems in this paper. We demonstr...
Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Tezcaner, Ayşen; Keskin, Dilek (2016-01-01)
Background: Nanoparticulate delivery systems receive a lot of attention in pharmaceutical research and market due to their in vivo stability, ability to protect entrapped drug, and ease of cellular penetration. The hemo-compatibility and the clearance half-life are important parameters of the nanodelivery systems that will be administered through intravenous route. Natural components, like blood plasma proteins are ideal sources of biomaterial for such systems with their long in vivo half-lives. Methods: Th...
Surface functionalization of SBA - 15 particles for amoxicillin delivery
Sevimli, Filiz F; Yılmaz, Ayşen; Department of Chemistry (2011)
There are several studies in order to control drug delivery, decrease the toxicity of drugs and also for novel biomedical applications. It is necessary to be able to control the release of the drug within the body by using drug delivery systems. Mesoporous silica compounds have only been discovered twenty years ago and they have already attracted many researchers to study these materials for several applications. SBA-15 particles have a highly ordered regular structure and are a good matrix for guest-host a...
DEEPScreen: high performance drug-target interaction prediction with convolutional neural networks using 2-D structural compound representations
Rifaioğlu, Ahmet Süreyya; Nalbat, Esra; Atalay, Mehmet Volkan (2020-03-07)
The identification of physical interactions between drug candidate compounds and target biomolecules is an important process in drug discovery. Since conventional screening procedures are expensive and time consuming, computational approaches are employed to provide aid by automatically predicting novel drug-target interactions (DTIs). In this study, we propose a large-scale DTI prediction system, DEEPScreen, for early stage drug discovery, using deep convolutional neural networks. One of the main advantage...
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
M. PARLAK KHALİLY and M. Soydan, “Peptide-based diagnostic and therapeutic agents: Where we are and where we are heading?,”
CHEMICAL BIOLOGY & DRUG DESIGN
, pp. 0–0, 2022, Accessed: 00, 2023. [Online]. Available: https://hdl.handle.net/11511/101491.